IPP Bureau

Ardigen supports JUMP-CP Consortium scaling up image-based drug discovery with the world’s largest public Cell Painting dataset
Ardigen supports JUMP-CP Consortium scaling up image-based drug discovery with the world’s largest public Cell Painting dataset

By IPP Bureau - October 28, 2022

The JUMP-CP Consortium’s aim is to validate and scale up image-based drug discovery strategies by creating the world’s largest public cell imaging data set

Gland Pharma’s Q2 FY23 revenue stood at Rs. 1,044.4 Cr
Gland Pharma’s Q2 FY23 revenue stood at Rs. 1,044.4 Cr

By IPP Bureau - October 27, 2022

Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr

Dabur India posts consolidated Q2 FY2023 PAT at Rs. 490.06 Cr
Dabur India posts consolidated Q2 FY2023 PAT at Rs. 490.06 Cr

By IPP Bureau - October 27, 2022

The company has reported total income of Rs. 3109.77 crores during the period ended September 30, 2022

Zydus gets USFDA’s approval for Ketorolac Tromethamine Tablets
Zydus gets USFDA’s approval for Ketorolac Tromethamine Tablets

By IPP Bureau - October 27, 2022

Ketorolac Tromethamine Tablets are indicated to relieve moderately severe pain, usually after surgery.

USFDA Issues a CRL for the Biologics License Application for Insulin Aspart
USFDA Issues a CRL for the Biologics License Application for Insulin Aspart

By IPP Bureau - October 27, 2022

The CRL did not identify any outstanding scientific issues with the product.

Camizestrant significantly improved PFS vs. Faslodex in SERENA-2 Phase II trial
Camizestrant significantly improved PFS vs. Faslodex in SERENA-2 Phase II trial

By IPP Bureau - October 27, 2022

Results reinforce commitment to next-generation oral SERD development programme

Robert M. Davis is the new Chairman of Merck
Robert M. Davis is the new Chairman of Merck

By IPP Bureau - October 27, 2022

Frazier led the company for 10 years as President and Chief Executive Officer, from 2011 through 2021.

ERES IV acquires a majority stake in Oncodesign Services
ERES IV acquires a majority stake in Oncodesign Services

By IPP Bureau - October 27, 2022

Oncodesign Services (ODS ), with 600 clients in 33 countries and 227 employees worldwide, provides services from target identification to hit-to-lead and lead optimization through to IND filing.

Laurus Labs planning Rs. 2,000 Cr Capex
Laurus Labs planning Rs. 2,000 Cr Capex

By IPP Bureau - October 27, 2022

On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions

CEPI and SK bioscience partner to advance mRNA vaccine technology
CEPI and SK bioscience partner to advance mRNA vaccine technology

By IPP Bureau - October 26, 2022

CEPI will provide up to US$40 million in initial funding to support the development of mRNA-vaccine candidates against Lassa Fever virus

Healthcare firms discover ways to use VR to treat neurological diseases, says GlobalData
Healthcare firms discover ways to use VR to treat neurological diseases, says GlobalData

By IPP Bureau - October 26, 2022

The global VR market to grow at a compound annual growth rate of 13% from $7 billion in 2018 to $28 billion in 2030.

Quizartinib granted priority review in the U.S.
Quizartinib granted priority review in the U.S.

By IPP Bureau - October 26, 2022

Submission based on QuANTUM-First results showing quizartinib plus chemotherapy significantly improved overall survival compared to chemotherapy alone

USFDA approves Imjudo in combination with Imfinzi for liver cancer
USFDA approves Imjudo in combination with Imfinzi for liver cancer

By IPP Bureau - October 26, 2022

Approval based on HIMALAYA Phase III trial results which showed single priming dose of Imjudo added to Imfinzi reduced risk of death by 22% vs. sorafenib

Novartis maintains growth momentum; Confirms FY’22 Group guidance
Novartis maintains growth momentum; Confirms FY’22 Group guidance

By IPP Bureau - October 26, 2022

Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.

AstraZeneca updates on the MESSINA Phase III trial for Fasenra in eosinophilic esophagitis
AstraZeneca updates on the MESSINA Phase III trial for Fasenra in eosinophilic esophagitis

By IPP Bureau - October 26, 2022

High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary endpoints.

Latest Stories

Interviews

Packaging